Effects of TRAIL and taurolidine on apoptosis and proliferation in human rhabdomyosarcoma, leiomyosarcoma and epithelioid cell sarcoma

Karlisch,C.; Harati,K.; Chromik,A. M.; Bulut,D.; Klein-Hitpass,L.; Goertz,O.; Hirsch,T.; Lehnhardt,M.; Uhl,W.; Daigeler,A.

doi:10.3892/ijo.2013.1772

Effects of TRAIL and taurolidine on apoptosis and proliferation in human rhabdomyosarcoma, leiomyosarcoma and epithelioid cell sarcoma

Authors:
- C. Karlisch
- K. Harati
- A. M. Chromik
- D. Bulut
- L. Klein-Hitpass
- O. Goertz
- T. Hirsch
- M. Lehnhardt
- W. Uhl
- A. Daigeler
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, Marienhospital Witten, Ruhr-University, D-58452 Witten, Germany, Department of Plastic Surgery, Burn Center, Hand Center, Sarcoma Reference Center, BG-University Hospital Bergmannsheil, D-44789 Bochum, Germany, Department of General and Visceral Surgery, St. Josef Hospital, Ruhr-University, D-44791 Bochum, Germany, Department of Medicine II, St. Josef Hospital, Ruhr-University, D-44791 Bochum, Germany, Institute for Cell Biology (Tumor Research), University of Duisburg-Essen, D-45122 Essen, Germany
Published online on: January 15, 2013 https://doi.org/10.3892/ijo.2013.1772
Pages: 945-956

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Soft tissue sarcomas (STS) are a heterogeneous group of malignant tumours representing 1% of all malignancies in adults. Therapy for STS should be individualised and multimodal, but complete surgical resection with clear margins remains the mainstay of therapy. Disseminated soft tissue sarcoma still represents a therapeutic dilemma. Commonly used chemotherapeutic agents such as doxorubicin and ifosfamide have proven to be effective in fewer than 30% in these cases. Therefore, we tested the apoptotic and anti‑proliferative in vitro effects of TNF-related apoptosis-inducing ligand (TRAIL) and taurolidine (TRD) on rhabdomyosarcoma (A-204), leiomyosarcoma (SK-LMS-1) and epithelioid cell sarcoma (VA-ES-BJ) cell lines. Viability, apoptosis and necrosis were quantified by FACS analysis (propidium iodide/Annexin V staining). Gene expression was analysed by DNA microarrays and the results validated for selected genes by rtPCR. Protein level changes were documented by western blot analysis. Cell proliferation was analysed by BrdU ELISA assay. The single substances TRAIL and TRD significantly induced apoptotic cell death and decreased proliferation in rhabdomyosarcoma and epithelioid cell sarcoma cells. The combined use of TRAIL and TRD resulted in a synergistic apoptotic effect in all three cell lines, especially in rhabdomyosarcoma cells leaving 18% viable cells after 48 h of incubation (p<0.05). Analysis of the differentially regulated genes revealed that TRD and TRAIL influence apoptotic pathways, including the TNF-receptor associated and the mitochondrial pathway. Microarray analysis revealed remarkable expression changes in a variety of genes, which are involved in different apoptotic pathways and cross talk to other pathways at multiple levels. This in vitro study demonstrates that TRAIL and TRD synergise in inducing apoptosis and inhibiting proliferation in different human STS cell lines. Effects on gene expression differ relevantly in the sarcoma entities. These results provide experimental support for in vivo trials assessing the effect of TRAIL and TRD in STS and sustain the approach of individualized therapy.

View Figures

View References

1	Hoos A, Lewis JJ and Brennan MF: Soft tissue sarcoma: prognostic factors and multimodal treatment. Chirurg. 71:787–794. 2000.(In German).
2	Patrikidou A, Domont J, Cioffi A and Le Cesne A: Treating soft tissue sarcomas with adjuvant chemotherapy. Curr Treat Options Oncol. 12:21–31. 2011. View Article : Google Scholar : PubMed/NCBI
3	Kaushal A and Citrin D: The role of radiation therapy in the management of sarcomas. Surg Clin North Am. 88:629–646. 2008. View Article : Google Scholar : PubMed/NCBI
4	O’Brien GC, Cahill RA, Bouchier-Hayes DJ and Redmond HP: Co-immunotherapy with interleukin-2 and taurolidine for progressive metastatic melanoma. Ir J Med Sci. 175:10–14. 2006.PubMed/NCBI
5	Solomon LR, Cheesbrough JS, Bhargava R, et al: Observational study of need for thrombolytic therapy and incidence of bacteremia using taurolidine-citrate-heparin, taurolidine-citrate and heparin catheter locks in patients treated with hemodialysis. Semin Dial. 25:233–238. 2012. View Article : Google Scholar
6	Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C and Judson I: Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer. 112:1585–1591. 2008. View Article : Google Scholar
7	Billingsley KG, Lewis JJ, Leung DH, Casper ES, Woodruff JM and Brennan MF: Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma. Cancer. 85:389–395. 1999. View Article : Google Scholar : PubMed/NCBI
8	Pezzi CM, Pollock RE, Evans HL, et al: Preoperative chemo-therapy for soft-tissue sarcomas of the extremities. Ann Surg. 211:476–481. 1990. View Article : Google Scholar : PubMed/NCBI
9	Donato Di Paola E and Nielsen OS: The EORTC soft tissue and bone sarcoma group. European Organisation for Research and Treatment of Cancer. Eur J Cancer. 38(Suppl 4): S138–S141. 2002.
10	Nedea EA and DeLaney TF: Sarcoma and skin radiation oncology. Hematol Oncol Clin North Am. 20:401–429. 2006. View Article : Google Scholar : PubMed/NCBI
11	Brodowicz T, Schwameis E, Widder J, et al: Intensified adjuvant IFADIC chemotherapy for adult soft tissue sarcoma: a prospective randomized feasibility trial. Sarcoma. 4:151–160. 2000. View Article : Google Scholar : PubMed/NCBI
12	Frustaci S, Gherlinzoni F, De Paoli A, et al: Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 19:1238–1247. 2001.PubMed/NCBI
13	Bramwell V, Rouesse J, Steward W, et al: Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma - reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 12:1137–1149. 1994.
14	Sarcoma Meta-analysis Collaboration: Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet. 350:1647–1654. 1997. View Article : Google Scholar : PubMed/NCBI
15	Hirata T, Yonemori K, Ando M, et al: Efficacy of taxane regimens in patients with metastatic angiosarcoma. Eur J Dermatol. 21:539–545. 2011.PubMed/NCBI
16	Penel N, Van Glabbeke M, Marreaud S, Ouali M, Blay JY and Hohenberger P: Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. Ann Oncol. 22:1266–1272. 2011.PubMed/NCBI
17	Mentzel T: Epithelioid sarcoma: morphologic variants and differential diagnosis. Pathologe. 31:135–141. 2010.PubMed/NCBI
18	Chromik AM, Daigeler A, Bulut D, et al: Comparative analysis of cell death induction by Taurolidine in different malignant human cancer cell lines. J Exp Clin Cancer Res. 29:212010. View Article : Google Scholar : PubMed/NCBI
19	Chromik AM, Daigeler A, Hilgert C, et al: Synergistic effects in apoptosis induction by taurolidine and TRAIL in HCT-15 colon carcinoma cells. J Invest Surg. 20:339–348. 2007. View Article : Google Scholar : PubMed/NCBI
20	Daigeler A, Chromik AM, Geisler A, et al: Synergistic apoptotic effects of taurolidine and TRAIL on squamous carcinoma cells of the esophagus. Int J Oncol. 32:1205–1220. 2008. View Article : Google Scholar : PubMed/NCBI
21	Daigeler A, Chromik AM, Haendschke K, et al: Synergistic effects of sonoporation and taurolidin/TRAIL on apoptosis in human fibrosarcoma. Ultrasound Med Biol. 36:1893–1906. 2010. View Article : Google Scholar : PubMed/NCBI
22	Yagita H, Takeda K, Hayakawa Y, Smyth MJ and Okumura K: TRAIL and its receptors as targets for cancer therapy. Cancer Sci. 95:777–783. 2004. View Article : Google Scholar : PubMed/NCBI
23	Bouralexis S, Findlay DM and Evdokiou A: Death to the bad guys: targeting cancer via Apo2L/TRAIL. Apoptosis. 10:35–51. 2005. View Article : Google Scholar : PubMed/NCBI
24	Rowinsky EK: Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol. 23:9394–9407. 2005. View Article : Google Scholar
25	Ashkenazi A, Pai RC, Fong S, et al: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 104:155–162. 1999. View Article : Google Scholar : PubMed/NCBI
26	Ganten D, Ruckpaul K and Daniel P: Molekulare Grundlagen der Apoptose. Grundlagen der Molekularen Medizin. Springer Berlin; Heidelberg: pp. 159–203. 2008
27	Newsom-Davis T, Prieske S and Walczak H: Is TRAIL the holy grail of cancer therapy? Apoptosis. 14:607–623. 2009. View Article : Google Scholar : PubMed/NCBI
28	LeBlanc HN and Ashkenazi A: Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 10:66–75. 2003. View Article : Google Scholar : PubMed/NCBI
29	Beere HM: Death versus survival: functional interaction between the apoptotic and stress-inducible heat shock protein pathways. J Clin Invest. 115:2633–2639. 2005. View Article : Google Scholar : PubMed/NCBI
30	Jacobi CA, Menenakos C and Braumann C: Taurolidine - a new drug with anti-tumor and anti-angiogenic effects. Anticancer Drugs. 16:917–921. 2005. View Article : Google Scholar : PubMed/NCBI
31	McCourt M, Wang JH, Sookhai S and Redmond HP: Taurolidine inhibits tumor cell growth in vitro and in vivo. Ann Surg Oncol. 7:685–691. 2000. View Article : Google Scholar : PubMed/NCBI
32	Petrovic L, Schlegel KA, Ries J, et al: In vitro effect of taurolidine on squamous cell carcinoma in the oral cavity. Mund Kiefer Gesichtschir. 7:102–107. 2003.(In German).
33	Gallagher KA, Liu ZJ, Xiao M, et al: Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. J Clin Invest. 117:1249–1259. 2007. View Article : Google Scholar : PubMed/NCBI
34	Calabresi P, Goulette FA and Darnowski JW: Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent. Cancer Res. 61:6816–6821. 2001.PubMed/NCBI
35	Braumann C, Henke W, Jacobi CA and Dubiel W: The tumor-suppressive reagent taurolidine is an inhibitor of protein biosynthesis. Int J Cancer. 112:225–230. 2004. View Article : Google Scholar : PubMed/NCBI
36	Neary PM, Hallihan P, Wang JH, Pfirrmann RW, Bouchier-Hayes DJ and Redmond HP: The evolving role of taurolidine in cancer therapy. Ann Surg Oncol. 17:1135–1143. 2010. View Article : Google Scholar : PubMed/NCBI
37	Darnowski JW, Goulette FA, Cousens LP, Chatterjee D and Calabresi P: Mechanistic and antineoplastic evaluation of taurolidine in the DU145 model of human prostate cancer. Cancer Chemother Pharmacol. 54:249–258. 2004. View Article : Google Scholar : PubMed/NCBI
38	Stendel R, Biefer HR, Dekany GM, et al: The antibacterial substance taurolidine exhibits anti-neoplastic action based on a mixed type of programmed cell death. Autophagy. 5:194–210. 2009. View Article : Google Scholar : PubMed/NCBI
39	Stendel R, Scheurer L, Stoltenburg-Didinger G, Brock M and Mohler H: Enhancement of Fas-ligand-mediated programmed cell death by taurolidine. Anticancer Res. 23:2309–2314. 2003.PubMed/NCBI
40	Daigeler A, Brenzel C, Bulut D, et al: TRAIL and Taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma. J Exp Clin Cancer Res. 27:822008. View Article : Google Scholar : PubMed/NCBI
41	Han Z, Ribbizi I, Pantazis P, Wyche J, Darnowski J and Calabresi P: The antibacterial drug taurolidine induces apoptosis by a mitochondrial cytochrome c-dependent mechanism. Anticancer Res. 22:1959–1964. 2002.PubMed/NCBI
42	Braumann C, Winkler G, Rogalla P, Menenakos C and Jacobi CA: Prevention of disease progression in a patient with a gastric cancer-re-recurrence. Outcome after intravenous treatment with the novel antineoplastic agent taurolidine Report of a case. World J Surg Oncol. 4:342006. View Article : Google Scholar
43	Imhof L, Goldinger SM, Baumann K, et al: The antibacterial substance, taurolidine in the second/third-line treatment of very advanced stage IV melanoma including brain metastases: results of a phase 2, open-label study. Melanoma Res. Nov 3–2010.(Epub ahead of print).
44	Stendel R, Picht T, Schilling A, et al: Treatment of glioblastoma with intravenous taurolidine. First clinical experience. Anticancer Res. 24:1143–1147. 2004.PubMed/NCBI
45	Backes C, Keller A, Kuentzer J, et al: GeneTrail - advanced gene set enrichment analysis. Nucleic Acids Res. 35:W186–W192. 2007. View Article : Google Scholar : PubMed/NCBI
46	Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A and Ashkenazi A: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 271:12687–12690. 1996. View Article : Google Scholar : PubMed/NCBI
47	Wiley SR, Schooley K, Smolak PJ, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3:673–682. 1995. View Article : Google Scholar : PubMed/NCBI
48	Tomek S, Koestler W, Horak P, et al: Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines. Eur J Cancer. 39:1318–1329. 2003. View Article : Google Scholar : PubMed/NCBI
49	Clayer M, Bouralexis S, Evdokiou A, Hay S, Atkins GJ and Findlay DM: Enhanced apoptosis of soft tissue sarcoma cells with chemotherapy: A potential new approach using TRAIL. J Orthop Surg (Hong Kong). 9:19–22. 2001.PubMed/NCBI
50	Kondo K, Yamasaki S, Inoue N, et al: Prospective antitumor effects of the combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin against esophageal squamous cell carcinoma. Surg Today. 36:966–974. 2006. View Article : Google Scholar
51	Walters DK, Muff R, Langsam B, Gruber P, Born W and Fuchs B: Taurolidine: a novel anti-neoplastic agent induces apoptosis of osteosarcoma cell lines. Invest New Drugs. 25:305–312. 2007. View Article : Google Scholar : PubMed/NCBI
52	Kluttermann K, Banning U, Kachel M, Krause C, Korholz D and Mauz-Korholz C: TRAIL-induced cytotoxicity in a melphalan-resistant rhabdomyosarcoma cell line via activation of caspase-2. Anticancer Res. 26:351–356. 2006.PubMed/NCBI
53	Komdeur R, Meijer C, Van Zweeden M, et al: Doxorubicin potentiates TRAIL cytotoxicity and apoptosis and can overcome TRAIL-resistance in rhabdomyosarcoma cells. Int J Oncol. 25:677–684. 2004.PubMed/NCBI
54	Heikaus S, Matuszek KS, Suschek CV, et al: Paclitaxel (Taxol)-induced apoptosis in human epithelioid sarcoma cell lines is enhanced by upregulation of CD95 ligand (FasL/Apo-1L). J Cancer Res Clin Oncol. 134:689–695. 2008. View Article : Google Scholar : PubMed/NCBI
55	Gheorghescu B, Gherman I, Jovin GH, et al: Absorption studies in patients with parasitic infestation of the small intestine, before and after treatment. Med Interne. 14:31–38. 1976.PubMed/NCBI
56	Nedeau AE, Gallagher KA, Liu ZJ and Velazquez OC: Elevation of hemopexin-like fragment of matrix metalloproteinase-2 tissue levels inhibits ischemic wound healing and angiogenesis. J Vasc Surg. 54:1430–1438. 2011. View Article : Google Scholar : PubMed/NCBI
57	Nedea ME, Vasilescu F, Gheorghescu B, Pavelescu E and Runcan V: Determination with thin layer chromatography of the distribution of lipids in the feces and study of the incorporation of certain C 14 -labeled 1-fatty acids into the different lipid fractions. Fiziol Norm Patol. 19:67–73. 1973.(In Romanian).
58	Hollander MC, Poola-Kella S and Fornace AJ: Gadd34 functional domains involved in growth suppression and apoptosis. Oncogene. 22:3827–3832. 2003. View Article : Google Scholar : PubMed/NCBI
59	Hollander MC, Zhan Q, Bae I and Fornace AJ Jr: Mammalian GADD34, an apoptosis- and DNA damage-inducible gene. J Biol Chem. 272:13731–13737. 1997. View Article : Google Scholar : PubMed/NCBI
60	Adler HT, Chinery R, Wu DY, et al: Leukemic HRX fusion proteins inhibit GADD34–induced apoptosis and associate with the GADD34 and hSNF5/INI1 proteins. Mol Cell Biol. 19:7050–7060. 1999.PubMed/NCBI
61	Grishin AV, Azhipa O, Semenov I and Corey SJ: Interaction between growth arrest-DNA damage protein 34 and Src kinase Lyn negatively regulates genotoxic apoptosis. Proc Natl Acad Sci USA. 98:10172–10177. 2001. View Article : Google Scholar : PubMed/NCBI
62	Chromik AM, Hahn SA, Daigeler A, et al: Gene expression analysis of cell death induction by taurolidine in different malignant cell lines. BMC Cancer. 10:5952010. View Article : Google Scholar : PubMed/NCBI
63	Rohde M, Daugaard M, Jensen MH, Helin K, Nylandsted J and Jaattela M: Members of the heat-shock protein 70 family promote cancer cell growth by distinct mechanisms. Genes Dev. 19:570–582. 2005. View Article : Google Scholar : PubMed/NCBI
64	Daugaard M, Rohde M and Jaattela M: The heat shock protein 70 family: highly homologous proteins with overlapping and distinct functions. FEBS Lett. 581:3702–3710. 2007. View Article : Google Scholar : PubMed/NCBI
65	Noguchi T, Takeno S, Shibata T, Uchida Y, Yokoyama S and Muller W: Expression of heat shock protein 70 in grossly resected esophageal squamous cell carcinoma. Ann Thorac Surg. 74:222–226. 2002. View Article : Google Scholar : PubMed/NCBI
66	Huang WJ, Xia LM, Zhu F, et al: Transcriptional upregulation of HSP70-2 by HIF-1 in cancer cells in response to hypoxia. Int J Cancer. 124:298–305. 2009. View Article : Google Scholar : PubMed/NCBI
67	Scieglinska D, Piglowski W, Mazurek A, et al: The HspA2 protein localizes in nucleoli and centrosomes of heat shocked cancer cells. J Cell Biochem. 104:2193–2206. 2008. View Article : Google Scholar : PubMed/NCBI
68	Garg M, Kanojia D, Seth A, et al: Heat-shock protein 70-2 (HSP70-2) expression in bladder urothelial carcinoma is associated with tumour progression and promotes migration and invasion. Eur J Cancer. 46:207–215. 2010. View Article : Google Scholar : PubMed/NCBI
69	Grivicich I, Regner A, Zanoni C, et al: Hsp70 response to 5-fluorouracil treatment in human colon cancer cell lines. Int J Colorectal Dis. 22:1201–1208. 2007. View Article : Google Scholar : PubMed/NCBI
70	Park SR, Lee KD, Kim UK, et al: Pseudomonas aeruginosa exotoxin A reduces chemoresistance of oral squamous carcinoma cell via inhibition of heat shock proteins 70 (HSP70). Yonsei Med J. 51:708–716. 2010. View Article : Google Scholar : PubMed/NCBI
71	Beere HM: ‘The stress of dying’: the role of heat shock proteins in the regulation of apoptosis. J Cell Sci. 117:2641–2651. 2004.
72	Valoti G, Nicoletti MI, Pellegrino A, et al: Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res. 4:1977–1983. 1998.PubMed/NCBI
73	Zhang L and Fang B: Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 12:228–237. 2005. View Article : Google Scholar : PubMed/NCBI
74	Kuang AA, Diehl GE, Zhang J and Winoto A: FADD is required for DR4- and DR5-mediated apoptosis: lack of trail-induced apoptosis in FADD-deficient mouse embryonic fibroblasts. J Biol Chem. 275:25065–25068. 2000. View Article : Google Scholar : PubMed/NCBI
75	Bodmer JL, Holler N, Reynard S, et al: TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol. 2:241–243. 2000. View Article : Google Scholar : PubMed/NCBI
76	Petak I, Vernes R, Szucs KS, et al: A caspase-8-independent component in TRAIL/Apo-2L-induced cell death in human rhabdomyosarcoma cells. Cell Death Differ. 10:729–739. 2003. View Article : Google Scholar : PubMed/NCBI
77	Piras V, Hayashi K, Tomita M and Selvarajoo K: Enhancing apoptosis in TRAIL-resistant cancer cells using fundamental response rules. Sci Rep. 1:1442011. View Article : Google Scholar : PubMed/NCBI
78	Duckett CS: Apoptosis and NF-kappa B: the FADD connection. J Clin Invest. 109:579–580. 2002. View Article : Google Scholar : PubMed/NCBI
79	Park JM, Kim A, Oh JH and Chung AS: Methylseleninic acid inhibits PMA-stimulated pro-MMP-2 activation mediated by MT1-MMP expression and further tumor invasion through suppression of NF-kappaB activation. Carcinogenesis. 28:837–847. 2007. View Article : Google Scholar : PubMed/NCBI
80	Fiscella M, Zhang H, Fan S, et al: Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci USA. 94:6048–6053. 1997. View Article : Google Scholar : PubMed/NCBI
81	Lambros MB, Natrajan R, Geyer FC, et al: PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study. Mod Pathol. 23:1334–1345. 2010. View Article : Google Scholar : PubMed/NCBI
82	Natrajan R, Lambros MB, Rodriguez-Pinilla SM, et al: Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res. 15:2711–2722. 2009. View Article : Google Scholar : PubMed/NCBI
83	Tan DS, Lambros MB, Rayter S, et al: PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res. 15:2269–2280. 2009. View Article : Google Scholar : PubMed/NCBI
84	Xia Y, Ongusaha P, Lee SW and Liou Y-C: Loss of Wip1 sensitizes cells to stress- and DNA damage-induced apoptosis. J Biol Chem. 284:17428–17437. 2009. View Article : Google Scholar : PubMed/NCBI
85	Saito-Ohara F, Imoto I, Inoue J, et al: PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res. 63:1876–1883. 2003.PubMed/NCBI
86	Loukopoulos P, Shibata T, Katoh H, et al: Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: identification of genetic indicators that predict patient outcome. Cancer Sci. 98:392–400. 2007. View Article : Google Scholar
87	Fuku T, Semba S, Yutori H and Yokozaki H: Increased wild-type p53-induced phosphatase 1 (Wip1 or PPM1D) expression correlated with downregulation of checkpoint kinase 2 in human gastric carcinoma. Pathol Int. 57:566–571. 2007. View Article : Google Scholar : PubMed/NCBI
88	Castellino RC, De Bortoli M, Lu X, et al: Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D. J Neurooncol. 86:245–256. 2008. View Article : Google Scholar : PubMed/NCBI
89	Lu X, Nguyen TA, Moon SH, Darlington Y, Sommer M and Donehower LA: The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev. 27:123–135. 2008. View Article : Google Scholar : PubMed/NCBI
90	Rayter S, Elliott R, Travers J, et al: A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. Oncogene. 27:1036–1044. 2008. View Article : Google Scholar : PubMed/NCBI
91	Sorensen CS and Syljuasen RG: Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication. Nucleic Acids Res. 40:477–486. 2012. View Article : Google Scholar : PubMed/NCBI
92	Mir SE, De Witt Hamer PC, Krawczyk PM, et al: In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell. 18:244–257. 2010. View Article : Google Scholar : PubMed/NCBI
93	Iorns E, Lord CJ, Grigoriadis A, et al: Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PloS One. 4:e51202009. View Article : Google Scholar : PubMed/NCBI
94	Posthuma DeBoer J, Wurdinger T, Graat HC, et al: WEE1 inhibition sensitizes osteosarcoma to radiotherapy. BMC Cancer. 11:1562011.PubMed/NCBI
95	Magnussen GI, Holm R, Emilsen E, Rosnes AK, Slipicevic A and Florenes VA: High expression of wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy. PloS One. 7:e382542012. View Article : Google Scholar : PubMed/NCBI
96	Hirai H, Iwasawa Y, Okada M, et al: Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther. 8:2992–3000. 2009. View Article : Google Scholar
97	Rajeshkumar NV, De Oliveira E, Ottenhof N, et al: MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res. 17:2799–2806. 2011. View Article : Google Scholar : PubMed/NCBI
98	Bridges KA, Hirai H, Buser CA, et al: MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res. 17:5638–5648. 2011. View Article : Google Scholar : PubMed/NCBI
99	Hirai H, Arai T, Okada M, et al: MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther. 9:514–522. 2010. View Article : Google Scholar : PubMed/NCBI
100	Kreahling JM, Gemmer JY, Reed D, Letson D, Bui M and Altiok S: MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells. Mol Cancer Ther. 11:174–182. 2012. View Article : Google Scholar : PubMed/NCBI
101	Saito YD, Jensen AR, Salgia R and Posadas EM: Fyn: a novel molecular target in cancer. Cancer. 116:1629–1637. 2010. View Article : Google Scholar : PubMed/NCBI
102	Chen Z-Y, Cai L, Bie P, et al: Roles of Fyn in pancreatic cancer metastasis. J Gastroenterol Hepatol. 25:293–301. 2010. View Article : Google Scholar : PubMed/NCBI
103	Koike K, Kogawa K, Takayama T, et al: Enhanced expression of type IV collagen-binding protein (p29) in Fyn-transfected murine fibrosarcoma cells. Jpn J Cancer Res. 93:1090–1099. 2002. View Article : Google Scholar : PubMed/NCBI